McKesson 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Second-quarter revenue increased 8% to $111 billion, with growth across all four operating segments, and adjusted earnings per diluted share increased 18% to $11.68.
- Gross profit increased 10% to $3.9 billion, operating profit increased 13% to $1.9 billion, and operating expenses as a percentage of gross profit improved by approximately 141 basis points year over year.
- Excluding the prior-year $25 million Norway divestiture contribution and $51 million of net gains from the sale of an equity investment and market positions within the U.S. Oncology network, adjusted earnings per diluted share increased 24%.
- North American Pharmaceutical revenue increased 6% to $91.4 billion and operating profit increased 22% to $1 billion; GLP-1 medication distribution revenue was $16 billion, up approximately $3 billion or 26% year over year and 8% sequentially.
- Oncology and Multispecialty revenue increased 24% to $15 billion and operating profit increased 8% to $427 million, or 23% excluding prior-year net gains of $51 million; same-store patient visits reached their highest level in recent quarters across the networks.
- Prescription Technology Solutions revenue increased 10% to $1.5 billion and operating profit increased 18% to $307 million; Medical-Surgical Solutions revenue increased 5% to $3.1 billion and operating profit decreased 10% to $225 million.
- McKesson completed its approximately $2.25 billion acquisition of Precision Medicine Group, which will report in Oncology and Multispecialty, and entered a definitive agreement to invest approximately $1.4 billion for a 49% minority interest in Option Care Health.
- McKesson ended the quarter with $6.5 billion in cash and cash equivalents and approximately $11.5 billion in total liquidity, generated $2.9 billion of free cash flow, and returned $990 million to shareholders through share repurchases and dividends.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please stand by. Welcome to McKesson's second quarter fiscal 2027 earnings conference call. Please be advised that today's conference is being recorded. At this time, I would like to turn the call over to Paula Adkison, SVP of Corporate Finance and Investor Relations.
Please go ahead. Thank you, operator.
Good afternoon and welcome everyone to McKesson's second quarter fiscal 2027 earnings call. Today, I am joined by Brian Tyler, our Chair and Chief Executive Officer, and Kenny Cheung, our Chief Financial Officer. Brian will lead off, followed by Kenny, and then we will move to a question-and-answer session. Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com, and to the risk factors section of our most recent annual and periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements.
Information about non-GAAP financial measures that we will discuss during this webcast, including the reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and guidance assumptions. With that, let me turn it over to Brian.
Good afternoon, everyone. Thank you for joining our call. Today, we reported another strong quarter, reflecting continued momentum across our business and disciplined execution against our strategic priorities. Second quarter revenues increased 8%, with growth across all segments, while adjusted earnings per diluted share increased 18% year-over-year. These results demonstrate the strength and resilience of McKesson's operating model, the momentum across our diversified healthcare platform, and our continued focus on delivering sustainable long-term value for our customers and partners, and importantly, for our shareholders. As a result of our strong performance and our confidence in the outlook for our business, we are raising our fiscal 2027 adjusted earnings per diluted share guidance to $45.60-$46.40 from the previous range of $44.20 to $45.00.
Our results continue to demonstrate the benefits of our strategic focus, differentiated capabilities, and disciplined capital deployment. Across the enterprise, we remain focused on advancing our mission of improving health outcomes for all while executing against the strategic priorities that we believe will drive long-term sustainable growth. Now, let's discuss how we're translating these priorities into actions across the enterprise. I'll start with our people and culture, which remain foundational to everything we do. We continue to invest in experiences and programs that strengthen our culture and support engagement, development, and well-being. Recently, we launched Family Forward, a new employee resource group that fosters connection and supports employees with caregiving responsibilities at every stage of life. We now have 12 employee-led resource groups across the company, and I am proud of how these groups enrich our culture and advance inclusion for all members of Team McKesson.
Our annual impact report, published in July, highlights additional examples of the progress we're making to advance health outcomes by supporting our communities, developing our people, and enabling our partners to improve care for patients. Building on a strong commitment to our mission and purpose, we continue to accelerate our enterprise strategy with a focus on strengthening our North American Pharmaceutical distribution business and advancing our growth platforms in oncology, multispecialty, and biopharma services. During the quarter, we were pleased to announce a strategic transaction that directly supports these priorities, our acquisition of Precision Medicine Group, which we closed this week. We're pleased to welcome PMG to McKesson as we advance our shared commitment to accelerating innovation and improving patient access to care. Expanding access to clinical trials is an important element of our oncology strategy, connecting innovation and drug development with community-based practices where patients receive care.
In 2022, we established our joint venture with Sarah Cannon Research Institute, bringing together The US Oncology Network's provider reach and practice management expertise with SCRI's research infrastructure and clinical trial expertise to support these practices. Precision Medicine Group builds on this foundation, adding complementary clinical research expertise in oncology, rare and orphan diseases, and cell and gene therapies. Its global footprint and experience conducting late-stage clinical trials broaden our ability to support clinical development and expand patient access to innovative therapies. The acquisition also advances our biopharma services strategy. Precision Medicine Group's market access and commercialization services complement our existing access and affordability solutions, broadening the support we can provide to biopharma partners as they bring their therapies to market.
In addition, last month, we signed a definitive agreement to make a strategic investment in Option Care Health, the nation's largest independent provider of home and alternate site infusion services. As specialty therapies grow in importance and complexity, this transaction reflects our conviction that care will increasingly be delivered in lower-cost community settings at or closer to home. McKesson knows this shift well. For over 25 years, we have supported The US Oncology Network and over 3,400 providers in delivering connected, high-quality care in the community. Option Care Health's clinical model and national infusion footprint across home and ambulatory sites are well aligned with these priorities. As a strategic investor, we look forward to bringing our specialty expertise to help broaden access to complex therapies and to support its continued growth.
We are pleased to partner with CD&R, which brings a strong track record of supporting companies and creating long-term value. CD&R will own a majority interest in Option Care Health at closing. The transaction is subject to customary closing conditions, including approval by Option Care Health stockholders and the receipt of required regulatory approvals. In our Oncology & Multispecialty platform, we are encouraged by strong market trends supported by drug innovation and stable utilization. As new therapies come to market, our deep expertise in specialty distribution and specialty pharmacy, together with our strong connections across community-based care, position us well to enable access to these medications. Within the oncology platform, we continue to reinforce our value to community-based providers by bringing together complementary capabilities, which include community-based practice management experience, clinical research expertise, and data-enabled capabilities.
As we welcome Precision Medicine Group, we are excited to build on this foundation and accelerate our strategy. Within our retina and ophthalmology platform, we welcome Spectrum Vision Partners and its over 150 providers to the PRISM Vision Group, further expanding its footprint. This is another meaningful addition to our platform. We are encouraged by its continued strong performance, which demonstrates its compelling value proposition to providers and their patients. Across oncology and other specialty areas, our distribution capabilities, data-enabled insights, clinical expertise, and experience supporting providers allow us to create value for customers and improve patient access to care. Within our biopharma services platform, we continue to see strong demand for solutions that improve medication access and affordability. As therapeutic innovation accelerates and the treatment landscape becomes more complex, our differentiated solutions are helping translate that innovation into meaningful access for patients.
Our platform connects providers, pharmacies, payers, and manufacturers through technology that is embedded in prescribing and dispensing workflows. We continue to expand our payer network, which now includes payers that represent 96% of U.S. prescription volume. This connectivity enables us to simplify administrative processes and address financial barriers at scale, helping patients start and stay on therapy while supporting biopharma partners across their product life cycles. The momentum across our biopharma services platforms continues to be broad-based. During the quarter, we added 67 new programs across 58 unique brands, representing a diversified portfolio of therapeutic areas in both access and affordability. We expanded connectivity with providers, with more of them exploring our automated solutions, including our recently introduced medical prior authorization capabilities.
We also saw growth in services that provide dedicated reimbursement specialists to help providers navigate insurance coverage and reimbursement challenges, reinforcing the value of hands-on expertise alongside our automated solutions. Looking ahead, we remain focused on leveraging technology and automation to enhance the functionality of our solutions and streamline workflows. By simplifying routine processes and complementing them with specialized expertise where greater support is needed, we can address a broad range of access and affordability barriers and strengthen the value we deliver to biopharma partners, providers, and patients. Let's turn to North American Pharmaceutical distribution. Our pharmaceutical distribution business continues to perform well, supported by stable market fundamentals, operational excellence, and our differentiated customer value proposition. Recently, we announced an extension of our pharmaceutical distribution relationship with CVS Health.
This agreement reflects the strength of our longstanding partnership of more than 25 years, the value of our distribution capabilities, and our ability to support customers at scale with reliability, efficiency, and service excellence. We value our relationship with customers across the healthcare ecosystem and remain focused on supporting their growth through consistent execution and the highest levels of service. Across this segment, we continue to see strong momentum, reflecting our unwavering commitment to customers, the consistent delivery of high-quality service, and a disciplined focus on operational excellence. This performance enables us to reinvest in the business, including our distribution network, supply chain capabilities, and technology infrastructure, which further strengthen the reliability, efficiency, and scale of our platform and position us to deliver sustainable long-term growth.
The strength of our business and our diversified capabilities position us well to drive continued growth amid evolving industry trends and a dynamic policy environment. We are committed to working closely with policymakers to advance thoughtful reforms that support patient and providers, expand access to care, and improve health outcomes. In closing, our strong second quarter results build on a strong record of execution and growth. We are pleased with the momentum of the underlying business, reinforcing our commitment to our strategic priorities. The Precision Medicine Group acquisition and our proposed investment in Option Care Health represent significant progress in expanding our capabilities and investing in areas of compelling long-term opportunity. Looking ahead, we are confident in our ability to deliver sustainable growth and long-term shareholder value. With that, let me turn it over to Kenny.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
